

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors


This update of the 2013 guideline will help ensure:

- Uniform approach to molecular testing
- Improved effectiveness of treatment for patients

2nd
Most common cancer in both



1:15 Develop lung cancer in a lifetime
1:17



26%  **25%** 
Die of lung cancer

New Evidence-based Recommendations:

- Patients with certain biomarkers can benefit from targeted therapy
- *EGFR*, *ALK*, and *ROS1* testing must be performed on all advance stage lung cancer patients



Review all of the new and updated recommendations



COLLEGE of AMERICAN
PATHOLOGISTS

IASLC
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER



Conquering Thoracic Cancers Worldwide



AMP
ASSOCIATION
FOR MOLECULAR
PATHOLOGY

Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [published online January 22, 2018]. *J Mol Diagn*. <https://doi.org/10.1016/j.jmoldx.2017.11.004>

American Cancer Society. Key Statistics for Lung Cancer. American Cancer Society website. <https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/key-statistics.html> Updated January 4, 2018. Accessed January 11, 2018.

© 2018 CAP, IASLC, AMP. All rights reserved.
26340.0118